Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.76 and traded as high as $0.98. Brainstorm Cell Therapeutics shares last traded at $0.9727, with a volume of 22,429 shares trading hands.
Brainstorm Cell Therapeutics Price Performance
The stock has a market cap of $10.73 million, a price-to-earnings ratio of -0.29 and a beta of 0.23. The company’s fifty day moving average price is $0.87 and its 200-day moving average price is $0.76.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
